Vaccines and Viral Vectors


The global infectious immunology market is forecast to reach $8.8 billion by 2017, growing at a compound annual growth rate (CAGR) of 6% during the period 2010-2017. The hepatitis infections fragment developed at 7% and was esteemed at $2 billion in 2010.

Cell signaling is part of a complex system of communication that administers basic cellular activities and coordinates cell activities. A Neutralizing antibody is an antibody which safeguards a cell from an antigen or infectious body by inhibiting or neutralizing any effect it has biologically. Cell-mediated immunity is an immune response that does not involve antibodies, but rather involves the activation of phagocytes, antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen.

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.
Viral vaccines contain either inactivated viruses or attenuated (alive but not capable of causing disease) viruses.
Inactivated or killed viral vaccines contain viruses, which have lost their ability to replicate and in order for it to bring about a response it contains more antigen than live vaccines. Attenuated or live vaccines contain the live form of the virus. These viruses are not pathogenic but are able to induce an immune response.
  • Applications of viral vectors
  • Advances in antiviral vaccine development
  • Types of Vaccines
  • DIVA Vaccines
  • Vectors in Gene Therapy

Related Conference of Vaccines and Viral Vectors

Vaccines and Viral Vectors Conference Speakers